Antallet af alvorlige bivirkninger samt antallet af rapporterede metabolismerelaterede bivirkninger, så som hypokalæmi, hyponatræmi og hyperuremi, var lavere i den gruppe, der blev behandlet med nifedipin.
The number of severe adverse events, as well as the number of reported metabolism-related adverse events such as hypokalaemia, hyponatraemia and hyperuremia, was lower in the group treated with nifedipine.